The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
Matthew R. Smith
Consultant or Advisory Role - Amgen; Bayer
Research Funding - Amgen
Robert E. Coleman
Honoraria - Amgen; Bayer; Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Laurence Klotz
Honoraria - Amgen; Ferring; Janssen; Sanofi
Research Funding - Ferring
Kenneth B. Pittman
No relevant relationships to disclose
Piotr Milecki
No relevant relationships to disclose
Rachel Wei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Arun Balakumaran
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karim Fizazi
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis